Lv3
344 积分 2023-05-06 加入
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party
3天前
已完结
How I Manage Chronic Myeloid Leukemia During Pregnancy
9天前
已完结
How I treat advanced phases of CML
9天前
已完结
How I evaluate and treat resistance and relapse in CML
9天前
已关闭
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
9天前
已关闭
HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
20天前
已关闭
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
21天前
已完结
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
22天前
已完结
Risk factors and reasons for switching from front‐line therapy in the Italian chronic myeloid leukaemia network: A cohort study
22天前
已完结
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability
1个月前
已完结
皖公网安备34019202002308
